Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LMTM Extension Study in AD or bvFTD
NCT02245568Phase 3Terminated
- Sponsor
- TauRx Therapeutics Ltd
- Start
- Aug 2014
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 17
01
Overview
A Phase 3 trial of hydromethylthionine mesylate in Alzheimer's disease (AD), frontotemporal dementia (FTD), sponsored by TauRx Therapeutics Ltd. Started Aug 2014; status: terminated.
02
Drugs
hydromethylthionine mesylate
03
Conditions
Alzheimer's disease (AD)frontotemporal dementia (FTD)
Beyond the preview
Go deeper on NCT02245568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02245568.